Symrise Wins Inaugural Award

The Event and Award Context

Cosmetics Business held the inaugural edition of its Cosmetics Business Innovation Awards (CBIAs), designed to recognize outstanding developments and achievements across the global cosmetics and personal care supply chain. This B2B-focused awards program spotlights excellence in ingredients, packaging, contract manufacturing, technology, testing, regulatory affairs, and compliance.

Symrise's Technical Approach

In a highly competitive category, judge Stewart Long praised Symrise for its risk assessment approach. This method aims to protect against harmful exposure to chemicals without relying on animal testing. Symrise utilized in vitro, in silico, and microbiome studies to evaluate developmental toxicity and conclude the safety of exposed workers.

Data Comparison and Regulatory Landscape

The manner in which Symrise framed its study, collected data, and compared its findings against existing teratogenicity animal data was noted as particularly strong. This study demonstrates an effective shift away from relying on animal studies to predict whether a chemical causes specific toxic effects. This transition is critically important under the European Union's regulations prohibiting unnecessary animal testing.

Implications for B2B Procurement and Compliance

For brand owners and procurement teams, this case highlights the value of non-animal testing methods for both compliance and efficiency. As EU regulations become more stringent, selecting suppliers that provide safety assessment reports supported by in vitro and in silico data helps brands avoid legal and ethical risks associated with animal experiments. Furthermore, B2B partners capable of validating new data against historical animal test results offer more compelling safety assurances for product development.